PMID- 20665394
OWN - NLM
STAT- MEDLINE
DCOM- 20101108
LR  - 20151119
IS  - 1098-9048 (Electronic)
IS  - 1069-3424 (Linking)
VI  - 31
IP  - 4
DP  - 2010 Aug
TI  - Cutaneous sarcoidosis.
PG  - 442-51
LID - 10.1055/s-0030-1262212 [doi]
AB  - Sarcoidosis is a systemic disease with skin manifestations. Skin manifestations 
      are classified as nonspecific if they are not characterized by granulomatous 
      inflammation and specific if the lesions have granulomas histologically. Erythema 
      nodosum is the most common nonspecific skin manifestation, and it portends a good 
      prognosis. Specific skin lesions have a varied clinical appearance, although 
      often they can be distinguished by their yellow translucent character. Despite 
      the potential variable appearance, there are common clinical presentations. Lupus 
      pernio lesions are nodular violaceous specific skin lesions found predominantly 
      on the face associated with scarring and a poor prognosis. Treatment of cutaneous 
      sarcoidosis is primarily done to avoid scarring and cosmetic disfigurement. Local 
      and systemic corticosteroids are the mainstay of treatment for the disease. 
      Corticosteroid-sparing agents used to manage the disease include antimalarials, 
      methotrexate, and tetracycline antibiotics. Tumor necrosis factor-alpha 
      (TNF-alpha) antagonists such as infliximab may have a role in cutaneous 
      sarcoidosis, especially in refractory cases that are resistant to the standard 
      regimens.
CI  - Copyright Thieme Medical Publishers.
FAU - Marchell, Richard M
AU  - Marchell RM
AD  - Department of Dermatology, Medical University of South Carolina, Charleston, SC 
      29425, USA. marchell@musc.edu
FAU - Judson, Marc A
AU  - Judson MA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100727
PL  - United States
TA  - Semin Respir Crit Care Med
JT  - Seminars in respiratory and critical care medicine
JID - 9431858
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Dermatologic Agents/therapeutic use
MH  - Erythema Nodosum/etiology/pathology/*therapy
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Infliximab
MH  - Prognosis
MH  - Sarcoidosis/pathology/*therapy
MH  - Skin Diseases/etiology/pathology/*therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2010/07/29 06:00
MHDA- 2010/11/09 06:00
CRDT- 2010/07/29 06:00
PHST- 2010/07/29 06:00 [entrez]
PHST- 2010/07/29 06:00 [pubmed]
PHST- 2010/11/09 06:00 [medline]
AID - 10.1055/s-0030-1262212 [doi]
PST - ppublish
SO  - Semin Respir Crit Care Med. 2010 Aug;31(4):442-51. doi: 10.1055/s-0030-1262212. 
      Epub 2010 Jul 27.